Dss, INC

DSS, Inc. has entered into a securities purchase agreement with related party Alset, Inc. to raise $1,000,000 through a convertible promissory note and warrants.

DSS, Inc. has entered into a securities purchase agreement to receive a $2.45 million loan from Alset International Limited, a related party, in exchange for a convertible promissory note and warrants.

DSS, Inc. announced the closing of an underwritten public offering, raising approximately $0.7 million in net proceeds for general corporate and working capital needs.

DSS, Inc. announced that its stockholders approved the election of all director nominees, ratified the appointment of its independent auditor, and approved executive compensation on an advisory basis at its 2025 annual meeting.

DSS, Inc. has converted an outstanding $12 million revolving promissory note owed by Impact Biomedical Inc. into 31,939,778 shares of Impact Biomedical common stock, fully settling the debt.

DSS, Inc. has dismissed Grassi & Co., CPAs, P.C. and appointed HTL International, LLC. as its new independent registered public accounting firm, effective June 27, 2025, with no reported disagreements with the former auditor.

DSS, Inc. reported a significant reduction in net loss for the third quarter and first nine months of 2025, driven by increased revenue in its Printed Products and Securities segments, despite ongoing liquidity challenges and internal control weaknesses.

DSS, Inc. reported a 27% increase in total revenue for the first half of 2025, reducing its net loss by 21%, but faces substantial doubt about its ability to continue as a going concern.

DSS Inc. reports a 28% increase in revenue for Q1 2025 compared to Q1 2024, but continues to experience net losses.

DSS Inc. experienced a mixed third quarter with increased revenue in some segments offset by losses and strategic changes impacting overall performance.

DSS Inc. experienced a significant decrease in revenue during the second quarter of 2024, primarily due to the deconsolidation of a major subsidiary and challenges in its rental and investment income streams.

DSS Inc. reported a significant decrease in revenue for the first quarter of 2024, primarily due to the deconsolidation of a major business segment and reduced sales in printed products.

DSS, Inc.'s 2024 annual report reveals a 26% decrease in revenue, driven by changes in business strategy and market conditions, alongside a strategic focus on operational efficiencies and long-term growth.

DSS Inc. has filed an amended 10-K report to restate its financial statements for 2023 and 2022, correcting a $23.5 million overstatement of a loss related to the deconsolidation of Sharing Services Global Corporation.

DSS Inc.'s 2023 annual report reveals a complex year marked by strategic business line adjustments, revenue declines, and significant impairment charges, alongside some positive developments in its packaging division.

SEC Form 4 filing details transactions involving convertible promissory notes and warrants for DSS Inc., with reporting persons including directors and 10% owners.

DSS Inc. filed an amended Form 4 to correct its beneficial ownership of IMPACT BIOMEDICAL INC. common stock, now totaling 545,024 shares.

DSS Director and 10% owner, Heng Fai Ambrose Chan, sold 130,679 shares of common stock for approximately $1.35 per share under a Rule 10b5-1 trading plan.

DSS, Inc. filed an amended Form 4 to clarify details regarding a $500,000 convertible promissory note issued to Alset Inc., an entity controlled by Director Chan Heng Fai Ambrose.

DSS, Inc. issued a $500,000 convertible promissory note to Alset Inc., an entity controlled by director and 10% owner Chan Heng Fai Ambrose, convertible at $0.86 per share.

DSS, Inc., a 10% owner and director of IMPACT BIOMEDICAL INC., has reported the sale of its entire beneficial ownership of common stock in two transactions totaling 161,000 shares.

DSS, Inc. filed an amendment to its definitive proxy statement, confirming the agenda for its 2025 Annual Meeting of Stockholders on December 3, 2025, which includes director elections, auditor ratification, and an advisory vote on executive compensation.

DSS, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, auditor ratification, and executive compensation, while disclosing significant related party transactions and financial reserves.

DSS, Inc. will hold its annual stockholders meeting on December 4, 2024, to elect directors, ratify the appointment of its accounting firm, and conduct an advisory vote on executive compensation.

DSS, Inc. is launching a reasonable best efforts offering of up to 8,333,333 shares of common stock and pre-funded warrants to raise approximately $8 million for working capital.

DSS, Inc. has filed a registration statement for a reasonable best efforts offering of up to $8 million in common stock and pre-funded warrants.

Heng Fai Ambrose Chan and affiliated entities report increased beneficial ownership in DSS Inc., holding over 86% through various holdings including convertible notes and warrants.

DSS Inc. reports a $500,000 convertible promissory note issuance to Alset Inc. and a share sale by its largest beneficial owner, Heng Fai Ambrose Chan.

DSS, Inc. issued a $500,000 convertible promissory note to Alset Inc., further solidifying the control of major shareholder Heng Fai Ambrose Chan and his affiliated entities.

Heng Fai Ambrose Chan and affiliated entities have significantly increased their beneficial ownership in DSS, Inc. to 67.6% of outstanding common stock through a recent stock grant and direct share purchases.